LEXINGTON, S.C., April 28 2006 /PRNewswire/ -- The U.S. Patent
and Trademark Office has awarded patent #7,029,712 to Biosyntrx's
BioTears Oral GelCaps(R), a dry eye, tear film integrity
formulation.
Nutrients included in the BioTears oral formulation have been
suggested in clinical studies to systemically control the
inflammatory process associated with dry eye syndrome (tear film
dysfunction). These nutrients also increase levels of tear
lactoferrin, an iron-binding protein that inhibits viral, bacterial
and fungal growth on the ocular surface.
"This is particularly important to the contact lens wearer," said
Ellen Troyer, MT MA, Biosyntrx's chief research officer and BioTears
co-inventor. "The BioTears formulation has also been suggested to
improve visual acuity after cataract and refractive surgery,
particularly following LASIK or implantation of multi-focal
intraocular lens." Sufficient lubricating tears are critical to eye
health and visual clarity, as well as being the first-line
protection for the ocular surface.
Spencer Thornton, MD, Nashville; president of Biosyntrx and
BioTears co- inventor, calls BioTears a "breakthrough formula."
BioTears are recommended by thousands of eye care professionals and
sold through their offices or through the Biosyntrx web site,
www.biosyntrx.com. BioTears Oral GelCaps are distributed in 37
countries.
The Biosyntrx Advisory Board includes well-known leaders in
ophthalmic science, including Howard Fine, MD, Eugene, OR; Jerre
Freeman, MD, Memphis; Richard Lindstrom, MD, Minneapolis; Marguerite
B. McDonald, MD, New Orleans; Randall Olson, MD, Salt Lake City;
Robert H. Osher, MD, Cincinnati; Paul Sternberg, MD, Nashville.
Also, Stephen Slade, MD, Houston; Roger Steinert, MD, Irvine, CA;
Steve Whiting, PhD, San Diego; Betty Kamen, PhD, San Francisco;
Burton Goldberg, PhD, Tiburon, CA; Marsha Raanan, MA, Chicago; Jeff
Anshel, OD, San Diego; John Lahr. OD, Cincinnati; and Louis J.
Catania, OD, Atlantic Beach, Florida.
Market Scope's 2004 Report on the Global Dry Eye Market projects
that dry eye therapeutics and exciting diagnostic technologies now
under development will propel the dry eye market segment to $1.45
billion by 2010.
Biosyntrx, Inc., a privately funded, vision-focused nutraceutical
company, is based in Lexington, SC, with research offices in
Colorado Springs, CO. Its primary products are BioTears Oral
GelCaps(R) and two full-spectrum multiples, Macula Complete(R) and
Oculair(R). Biosyntrx is committed to proving the science that
supports each formulation.
For additional product information, visit www.biosyntrx.com
